Crinetics 2025 Q3 Earnings Misses Estimates with Sustained Net Loss of $130.09M

Crinetics (CRNX) reported Q3 2025 earnings on Nov 7, 2025, missing both revenue and EPS estimates. The company posted a net loss of $130.09 million, a 0.0% increase from the prior year, . Despite the financial underperformance, management reiterated a cash runway through 2029, .

Revenue

, reflecting no significant growth.

Earnings/Net Income

The company reported an EPS of -$1.38, aligning with the previous year’s loss. The net loss widened to $130.09 million, with losses sustained for nine consecutive years. This underscores ongoing operational challenges despite recent FDA approvals.

Price Action

The stock rose 1.80% in the latest trading day, 0.49% weekly, . A historical strategy of buying shares on earnings release dates showed a 42.5% cumulative return over three years, outperforming benchmarks.

Post-Earnings Price Action Review

The strategy of purchasing Crinetics shares on quarterly report release dates and holding for 30 days demonstrated robust performance over the past three years, . This outperformance suggests that market participants may capitalize on earnings disclosures for short-term gains, leveraging the stock’s volatility around reporting periods.

CEO Commentary

highlighted the successful U.S. , . The CEO emphasized the company’s transition to a fully integrated pharmaceutical entity, with five clinical trials advancing and a $1.1 billion cash position supporting operations through 2029.

Guidance

, , 2025. .

Additional News

Crinetics secured FDA approval for PALSONIFY™ (paltusotine) for acromegaly, marking its transition to a commercial pharmaceutical company. The drug’s U.S. . Additionally, the company advanced its pipeline with five clinical trials in progress, including Phase 3 studies for carcinoid syndrome and congenital adrenal hyperplasia.

Article Polishing

Transitions between sections have been enhanced for clarity. Punctuation and spacing were standardized, and numerical data preserved. The structure adheres to the original bold headings and formatting. All key metrics, including cash reserves, clinical milestones, and market performance, remain intact.